BIOGEN INC.
Biogen is a global biopharmaceutical company that discovers, develops and delivers therapies for people with serious and complex diseases. Its focus areas include neurology, specialized immunology and rare diseases. Biogen markets medicines for multiple sclerosis, spinal muscular atrophy, Friedreich’s ataxia and amyotrophic lateral sclerosis, including TYSABRI, SPINRAZA, SKYCLARYS and QALSODY. It also commercializes biosimilars BENEPALI, IMRALDI and FLIXABI, and collaborates with Eisai on LEQEMBI for Alzheimer’s disease and Supernus on ZURZUVAE for postpartum depression. Through agreements with Genentech, Biogen holds business and financial rights to several anti-CD20 therapies. Biogen makes money by selling its medicines and biosimilars and through its commercial and financial rights under collaborations. It supports drug discovery and development through internal research and development, external collaborations and acquisitions. Its headquarters are in Cambridge, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BIIB in the last 30 days.
See all $BIIB insider activity →Guggenheim reaffirmed its Buy rating for Biogen and increased its price target to $300 from $280, suggesting an 18.3% upside from the Oct 30 close. Recent analyst price targets for Biogen range from $238 to $280.
HC Wainwright & Co. kept its Buy rating on Biogen and increased its price target to $270 from $251, suggesting a 6.5% upside from the last close. Recent analyst price targets for Biogen range from $238 to $300.
96% of 23 healthcare companies beat EPS estimates, 70% posted Y/Y earnings growth. All 23 showed Y/Y revenue growth. AbbVie (ABBV), Eli Lilly (LLY), Bristol Myers (BMY), Gilead (GILD), Regeneron (REGN), Biogen (BIIB), Illumina (ILMN) reported strong Q3 results, raising outlooks. Amgen (AMGN), Pfizer (PFE), others to report next week.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning BIIB (BIOGEN INC.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent BIIB coverage spans financial news and earnings.
Analyst upgrade suggests upside potential for Biogen.
Analyst upgrade may create modest buying pressure.
Earnings beat and raised guidance may lift sentiment.
Analyst buy rating and higher price target suggest upside pressure.
Street PT increase can support near-term sentiment, but the article is only an analyst note with no new company fundamentals.
AlphAI scores every news story that mentions BIIB with an AI model for sentiment and relevance, and aggregates insider trades from BIOGEN INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guggenheim reaffirmed its Buy rating for Biogen and increased its price target to $300 from $280, suggesting an 18.3% upside from the Oct 30 close. Recent analyst price targets for Biogen range from $238 to $280.
HC Wainwright & Co. kept its Buy rating on Biogen and increased its price target to $270 from $251, suggesting a 6.5% upside from the last close. Recent analyst price targets for Biogen range from $238 to $300.
96% of 23 healthcare companies beat EPS estimates, 70% posted Y/Y earnings growth. All 23 showed Y/Y revenue growth. AbbVie (ABBV), Eli Lilly (LLY), Bristol Myers (BMY), Gilead (GILD), Regeneron (REGN), Biogen (BIIB), Illumina (ILMN) reported strong Q3 results, raising outlooks. Amgen (AMGN), Pfizer (PFE), others to report next week.
TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB) with a $250.00 price target. Biogen's shares closed at $244.05. The company reported Q3 revenue of $2.8B and a net loss of $20.6M, down from last year's $2.45B revenue and $466.5M profit. Insider sentiment is negative, with recent sales by directors.
Canaccord Genuity reaffirmed its Buy rating on Biogen and increased its price target to $272 from $248, representing a 9.7% increase. This target suggests a 9.0% upside from Biogen's Oct 29 closing price of $249.65. Recent analyst price targets for Biogen range from $238 to $300.
Morgan Stanley kept Biogen's rating at Equal-Weight but increased its price target to $238 from $231, suggesting a 2.5% downside from the last close. Recent analyst targets for Biogen range from $225 to $300.
Freedom Broker raised its price target on Biogen (BIIB) to $275 from $255, citing strong quarterly results and resilient portfolio performance. The stock is near its 52-week high of $258.78. Biogen reported adjusted earnings of $2.62 per share on revenue of $2.8 billion, exceeding expectations. Several analysts have revised earnings upwards and raised price targets.
UBS reaffirmed its Buy rating for Biogen and increased its price target to $300 from $270, suggesting a 22.9% upside from the last close. Recent analyst targets for Biogen range from $225 to $290.
TD Cowen kept its Buy rating on Biogen and increased its price target to $260 from $250, suggesting a 6.5% upside from the Oct 28 close of $244.05. Recent analyst price targets for Biogen range from $225 to $290.
Wedbush kept its Neutral rating on Biogen but raised its price target to $225 from $212, suggesting a 7.8% downside from the last close. Recent analyst targets for Biogen range from $230 to $290.
